"A 508-bed acute care hospital offering a wide range of services including coronary care, day procedures, day oncology, emergency care, hospital-in-the-home, intensive care, maternity, paediatric (children’s) care, medical imaging and pathology."

During the past decade, Cabrini Hospital conducted 60 clinical trials. In the 10-year time frame, 60 clinical trials started and 31 clinical trials were completed, i.e. on average, 51.7% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 20 clinical trials were completed. i.e. 105.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cabrini Hospital" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Celgene" with 7 trials sponsored, "Pfizer" with 7 trials sponsored, "BeiGene" with 6 trials sponsored and "Australian and New Zealand Intensive Care Research Centre" with 6 trials sponsored. Other sponsors include 47 different institutions and companies that sponsored additional 45 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cabrini Hospital" #1 collaborator was "Astellas Pharma Inc" with 3 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "National Health and Medical Research Council, Australia" with 2 trials as a collaborator. Other collaborators include 40 different institutions and companies that were collaborators in the rest 50 trials.

According to Clinical.Site data, the most researched conditions in "Cabrini Hospital" are "Prostate Cancer" (5 trials), "Ulcerative Colitis" (5 trials), "Ovarian Cancer" (4 trials), "Carcinoma, Non-Small-Cell Lung" (3 trials) and "Colitis, Ulcerative" (3 trials). Many other conditions were trialed in "Cabrini Hospital" in a lesser frequency.

Most popular intervention types in "Cabrini Hospital" are "Drug" (70 trials), "Biological" (10 trials), "Other" (4 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "Carboplatin" (4 trials), "Filgotinib" (4 trials), "Gemcitabine" (4 trials) and "Paclitaxel" (4 trials). Other intervention names were less common.

The vast majority of trials in "Cabrini Hospital" are 72 trials for "All" genders, 8 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are 34 active trials in "Cabrini Hospital". 1 are not yet recruiting, 13 are recruiting, 17 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 47 completed trials in Cabrini Hospital, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Cabrini Hospital, 19 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".